Our Focus

Rapid SARS-CoV-2 Antibody & Antigen Testing

SARS-CoV-2 Antibody (IgM/IgG) Test – A rapid immunoassay for the qualitative detection of IgM and IgG antibodies to the virus SARS-CoV-2 for patients with signs and symptoms of COVID-19 disease. We hope that by providing reliable point-of-care diagnostics, this will allow healthcare professionals to respond effectively to the ongoing pandemic with a diagnostic for outreach testing/patient triage. The test kit can be operated with a single drop of fingerprick whole blood and without the need for any additional equipment.

SARS-CoV-2 Antigen Test – The Rapid SARS-CoV-2 Antigen Test is a colloidal gold enhanced, rapid immunochromatographic assay for qualitative detection of SARS-CoV-2 antigens in the nasopharyngeal specimen collected by the swab from individuals who are suspected of COVID-19 by healthcare professionals and trained health care workers as an aid in the diagnosis of SARS-CoV-2 infection. The test is suitable for use in hospitals, clinics, testing laboratories and other medical facilities.

HCV near patient screening

– 130-150 million people worldwide have chronic Hep C

– 160,000 cases of acute Hep C were reported in the U.S. in 2009

– Central & East Asia and North Africa have the highest Hep C rates

HCV treatment landscape – Over the past few years, the introduction of direct acting antivirals has revolutionized treatment for Hepatitis C. With short durations, minimum side effects, and over 90% cure rates, campaign for HCV eradication such as No Hep campaign has gradually risen as a top priority on public health agendas as experts have begun to recognize the impact of test and treat initiatives on reducing future healthcare burden. While these new medications are an exciting improvement, at present, only a small percentage of people know their status, and access to affordable and user-friendly tests is vital to the success of these test and treat initiatives.

Foundation of accurate HCV Testing:

– Provision of reliable, high quality, regulatory approved test kits

– Qualified, trained and supported testing personnel

– Quality-assured testing environments that address quality control, equipment management, accurate record-keeping and external quality assessment (EQA) schemes

Our responsibility – As we recognize the need for manufacturers to support this public health agenda, our partners products have taken great lengths to optimize its testing platform with refined bioactive materials and state-of-the-art manufacturing facilities to ensure that high quality tests can be implemented in the field. To meet the requirements of genotype variability and sub-optimal storage conditions, our partners have gone through great lengths to assure the quality of tests with internal validations and external qualifications that testify to the performance of the tests. We believe we carry the proper experience to meet the demands for quality and consistent supply that are required for manufacturers to responsibly impact the initiative against Hepatitis C.

HCV Care continuum stages –HCV care continuum are series of steps from initial case finding, diagnosis to ultimate SVR and cure

The early and accurate diagnosis of one’s HIV status is essential for care and introduction to treatment. Due to limitations in access to quality healthcare in many countries, diagnostic tests have needed to adapt to use in resource-limited settings. Tests should be easy to use and provide rapid results to ensure that patients can know their status at the point of care and receive Anti-Retroviral Treatment (ART) immediately.

90/ 90/ 90 Goal:

– 90% of all patients living with HIV will know their HIV status

– 90% of all patients living with HIV will receive antiretroviral theraphy

– 90% of all patients receiving antiretroviral theraphy will have viral suppression

The need for diagnostics that advance the agenda of HIV disease management has never been greater, and diagnostics must improve to meet these demands. The pace at which countries implement an optimal mix of centralized and POC diagnostic services tailored to their specific disease management needs will be key in achieving the goal of 90-90- 90 over the next decade.

Solution – It is now recognized in the international community that access to robust, high-quality, and affordable diagnostics in resource-limited settings must increase in order to facilitate the early detection of HIV/AIDS. As experts in infectious disease screening, we and our partners want to be part of the solution. Over the past three decades, InTec has worked closely with disease management experts to tackle some of the world’s biggest infectious disease epidemics. By continuing to optimize bio-raw material facilities and improve testing platforms, we have been able to help governments and NGOs bring screening to the point of care with high quality diagnostics at responsible prices.

The HIV Care Continuum – To direct HIV prevention resources most effectively, one needs to track the “HIV care continuum.” The HIV care continuum is the series of steps from the time a person is diagnosed with HIV through the successful treatment of their infection with HIV medications. The ultimate goal of HIV treatment is to achieve viral suppression, meaning the amount of HIV in the body is very low or undetectable. This is important for people with HIV to stay healthy, live longer and reduce their chances of passing HIV to others